Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 3/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 6/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834168 | 0.89 | CNR2 (0.48) | CNR2CCR2SERPINE1AKR1C4AKR1C3 | |
| SCHEMBL6833160 | 0.89 | CCR2 (0.61) | CA9CA2CCR2SERPINE1AKR1C4 | |
| SCHEMBL6834681 | 0.88 | CNR2 (0.48) | CNR2CCR2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL6834130 | 0.88 | CNR2 (0.52) | CA9CA2CNR2CCR2SERPINE1 | |
| SCHEMBL6834054 | 0.87 | ALDH1A1 (0.49) | CA9CA2CNR2CCR2SERPINE1 | |
| SCHEMBL6834137 | 0.85 | CNR2 (0.52) | CNR2CCR2ALDH1A1TSHRHTT | |
| SCHEMBL6833257 | 0.85 | HDAC3 (0.49) | CA9CA2CCR2SERPINE1AKR1C4 | |
| SCHEMBL6713348 | 0.82 | ROCK1 (0.41) | CA9CA2CNR2CCR2F10 | |
| SCHEMBL6833953 | 0.82 | SERPINE1 (0.48) | CA9CA2CCR2SERPINE1AKR1C4 | |
| SCHEMBL6833868 | 0.82 | SERPINE1 (0.48) | CA9CA2CCR2SERPINE1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CA9 2283/4885CA2 2212/4885CNR2 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.